Deramiocel FDA Extension: Phase 2 Data Faces Phase 3 Scrutiny in First-in-Class Cell Therapy Gamble

FDA Extends Review of Capricor's DMD Cell Therapy

The FDA has granted a three-month extension for its review of Capricor Therapeutics' cell therapy, deramiocel, for Duchenne muscular dystrophy (DMD). This decision follows a previous rejection last year and a recent contentious advisory committee meeting. Capricor Therapeutics has strategically paused all other pipeline projects to focus solely on securing regulatory approval for deramiocel, a move that has drawn criticism from at least one shareholder.

• The FDA has extended the PDUFA date for Capricor Therapeutics' Duchenne muscular dystrophy cell therapy, deramiocel, by three months. This regulatory delay comes after the therapy faced an initial rejection last year and was subject to a contentious advisory committee meeting, signaling ongoing scrutiny and potential broader implications for the cell therapy industry.
• Capricor Therapeutics has made a significant strategic shift by halting all other pipeline projects to prioritize the regulatory approval of deramiocel. This focused approach aims to dedicate all necessary resources to navigate the complex regulatory landscape, although the decision has been met with dissatisfaction from at least one shareholder advocating for change.
• Deramiocel is a cell therapy developed by Capricor Therapeutics specifically for Duchenne muscular dystrophy, a severe genetic disorder. The company has been actively pursuing regulatory clearance for this therapy since last year, highlighting the long and challenging path to bring innovative treatments to patients with rare diseases.

Deramiocel's Extended FDA Review and AdComm Implications

Recent clinical trials in Duchenne muscular dystrophy (DMD) have generated meaningful data across gene therapy and other intervention modalities, informing both regulatory decisions and clinical practice. The EMBARK trial represents one of the most comprehensive recent datasets in the field, evaluating a gene therapy approach in ambulatory pediatric patients.

• EMBARK Trial — Delandistrogene moxeparvovec: This Phase 3 trial evaluated a single intravenous dose of delandistrogene moxeparvovec (1.33 × 10¹⁴ vg/kg) in 125 ambulatory male patients with DMD aged 4 to <8 years. The primary endpoint — change from baseline in North Star Ambulatory Assessment (NSAA) total score at 52 weeks versus placebo — did not achieve statistical significance; however, key secondary endpoints including timed function tests indicated slowing or stabilization of disease progression.

• EMBARK Two-Year Efficacy Data: At 104 weeks, patients treated with delandistrogene moxeparvovec demonstrated statistically significant functional benefit versus an external control cohort across outcomes prognostic for delayed ambulation loss — specifically NSAA, Time to Rise, and 10-m Walk/Run. Micro-dystrophin expression and sarcolemmal localization were maintained through 64 weeks, supporting durability of the gene therapy effect.

• EMBARK Quantitative MRI Findings (52 Weeks): MR-based assessments at one year showed that treated patients experienced less disease progression than placebo-treated patients, with decreased fat accumulation and improved T2 signal versus placebo. The global statistical test supported an overall treatment benefit (P = .03), providing objective structural corroboration of the functional trends observed.

• EMBARK Safety Profile: Through 104 weeks, no new safety signals emerged beyond the Week 52 data cut, with no treatment-related deaths, no study discontinuations due to adverse events, and no clinically significant complement-mediated adverse events. Identified treatment-related adverse events requiring management consideration included vomiting, acute liver injury, myocarditis, and immune-mediated myositis — a profile described as manageable with appropriate monitoring and consistent with findings from earlier delandistrogene moxeparvovec clinical trials.

Addressing Persistent Unmet Needs in Duchenne Muscular Dystrophy

Despite meaningful regulatory progress — including approvals for Elevidys and exon-skipping therapies — substantial gaps remain in the DMD treatment landscape. Key unmet needs span multiple dimensions: diagnostic delays, age-related gaps in clinical evidence, and underserved patient subpopulations that have historically been excluded from or underrepresented in clinical trials.

• Diagnostic delay and newborn screening (NBS): The average age of diagnosis in the United States has remained at 4.5–5 years over the past four decades. NBS programs based on creatine kinase muscle isoform (CK-MM) measurement are gaining traction — Ohio and Minnesota have implemented DMD NBS — but adoption remains inconsistent across states, perpetuating delayed access to early intervention.

• Infants and young children (0–3 years): A critical evidence gap exists for this age group, with no established evidence-based clinical guidelines for DMD management in children under 3. NBS expansion is projected to bring approximately 880 infants annually into clinical settings, yet very little is known about early gross motor trajectories; 94% of boys with DMD demonstrate delays in gross motor skills across the age span relative to normative controls.

• Non-ambulatory patients: Although the FDA expanded approval of delandistrogene moxeparvovec (Elevidys) in June 2024 to include both ambulatory and non-ambulatory patients aged ≥4 years, this population remains underserved in clinical trial design. Enriching trials for patients with declining pulmonary function or upper limb capacity is feasible without restricting enrollment to non-ambulatory patients — notably, more than half of patients exhibit clinically significant deficits in FVC %-predicted and PUL 1.2 scores prior to loss of ambulation.

• Female carriers: Young female DMD carriers represent an emerging population requiring dedicated attention, with identification and clinical management protocols still in early development.

• Genotype-specific populations with limited therapeutic options: Exon-skipping therapies currently address approximately 27% of DMD cases, and clinical benefit remains incompletely established. First-generation exon 51-skipping antisense oligonucleotides (ASOs) demonstrated limited efficacy, driving development of next-generation ASO designs targeting novel binding sites — but substantial genotype-defined subpopulations remain without approved mutation-specific therapies.

The Evolving Treatment Landscape for Duchenne Muscular Dystrophy

The treatment landscape for Duchenne muscular dystrophy (DMD) has undergone substantial evolution across multiple therapeutic modalities. In the domain of antisense oligonucleotide (ASO) exon-skipping therapies, four agents — eteplirsen, golodirsen, viltolarsen, and casimersen — have received FDA approval, with long-term real-world data indicating a broad safety profile and demonstrable delay in muscle deterioration. However, limitations in exon-skipping efficacy and dystrophin protein restoration have spurred the development of second-generation peptide-ASO conjugates, which exhibit enhanced potency and the capacity to restore dystrophin in cardiac tissue. Novel chemical modifications and bioconjugations incorporating peptides or antibodies have further advanced cellular uptake, endosomal escape, and nuclear import. Early clinical findings with these next-generation compounds show meaningful improvements in molecular efficacy relative to first-generation agents, though their long-term safety profiles remain under evaluation.

Gene therapy has emerged as a pivotal area of clinical development, exemplified by delandistrogene moxeparvovec, an AAVrh74-based micro-dystrophin gene therapy indicated for ambulatory pediatric patients aged 4–5 years with DMD. In the Phase 3 EMBARK trial, the primary endpoint — change from baseline in North Star Ambulatory Assessment (NSAA) score at week 52 — did not achieve statistical significance (between-group difference: 0.65; 95% CI, −0.45 to 1.74; P = 0.2441). Nevertheless, micro-dystrophin expression at week 12 reached 34.29% in treated patients versus 0.00% in placebo recipients, and two-year data from EMBARK demonstrated statistically significant benefit over an external control cohort across functional outcomes prognostic for sustained ambulation, including NSAA, Time to Rise, and 10-metre Walk/Run. The safety profile through week 104 was manageable, with no treatment-related deaths or study discontinuations; however, real-world data from 11 commercially treated patients identified 15 treatment-related toxicities, encompassing gastrointestinal symptoms, liver enzyme abnormalities, acute liver injury, and troponin-I elevations.

Beyond gene therapy and ASO approaches, the approval of vamorolone has introduced a meaningful alternative to conventional corticosteroid use. In its pivotal 24-week randomised clinical trial, vamorolone at 6 mg/kg per day met the primary endpoint of time-to-stand velocity versus placebo (least-squares mean: +0.05 m/s versus −0.01 m/s; P = .002). Crucially, height percentile declined in prednisone-treated participants while improving with vamorolone, and bone turnover markers — which declined with prednisone — were preserved with vamorolone, supporting its potential as a safer long-term anti-inflammatory option. Complementing these clinical advances, CRISPR/Cas-based genome engineering strategies — including exon excision, exon reframing via insertion/deletion mutations, splice signal disruption, and templated point-mutation correction via homology-directed repair or base editing — represent a further frontier of preclinical and early clinical development in DMD.

Capricor's All-In Bet: The Future of Deramiocel in DMD

The ongoing regulatory journey for deramiocel, Capricor Therapeutics' cell therapy for Duchenne muscular dystrophy (DMD), has reached a pivotal moment with the FDA's recent three-month review extension. This decision follows a previous rejection and a contentious advisory committee meeting, underscoring the significant hurdles and intense scrutiny faced by novel cell therapies, particularly for rare and severe conditions like DMD.

DMD is a devastating, progressive disease characterized by both skeletal and cardiac muscle degeneration, leading to profound disability and premature death. Existing evidence suggests deramiocel, composed of cardiosphere-derived cells (CDCs), possesses anti-fibrotic and immunomodulatory properties that could address key pathological drivers of DMD. Notably, the HOPE-2 trial demonstrated that repeated intravenous infusions of deramiocel significantly attenuated the deterioration of upper limb function and improved cardiac measures in late-stage DMD patients. This intravenous route offers a less invasive and potentially more accessible treatment option compared to earlier intracoronary approaches.

Capricor's strategic decision to halt all other pipeline projects to focus solely on deramiocel's approval highlights the immense stakes involved. For patients, an approval could introduce a much-needed disease-modifying therapy, offering hope for improved quality of life and potentially slowing disease progression. However, the extended review signals that the FDA may still be grappling with aspects of the data, potentially related to the magnitude of benefit, long-term durability, or the management of observed hypersensitivity reactions. Furthermore, while HOPE-2 was positive, the broader context of cardiosphere-derived cells includes mixed results, such as the ALLSTAR trial in post-MI patients which failed its primary efficacy endpoint, reminding us that efficacy can be context-dependent. The development of a robust potency assay, as described in recent research, is a positive step towards ensuring manufacturing consistency and regulatory confidence in cell therapy products. The coming months will be critical, not only for Capricor and DMD patients but also for shaping the regulatory landscape for advanced cell therapies.